MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/alz.13764

Медицинская библиотека · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024

Clinical validation of the PrecivityAD2 blood test: A mass spectrometry-based test with algorithm combining %p-tau217 and Aβ42/40 ratio to identify presence of brain amyloid.

Meyer Matthew R, Kirmess Kristopher M, Eastwood Stephanie, Wente-Roth Traci L, Irvin Faith, Holubasch Mary S, Venkatesh Venky, Fogelman Ilana, Monane Mark, Hanna Lucy, Rabinovici Gil D, Siegel Barry A, Whitmer Rachel A, Apgar Charles, Bateman Randall J, Holtzman David M, Irizarry Michael, Verbel David, Sachdev Pallavi, Ito Satoshi, Contois John, Yarasheski Kevin E, Braunstein Joel B, Verghese Philip B, West Tim

СтатьяВалидационное исследованиеПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

With the availability of disease-modifying therapies for Alzheimer's disease (AD), it is important for clinicians to have tests to aid in AD diagnosis, especially when the presence of amyloid pathology is a criterion for receiving treatment.

METHODS

High-throughput, mass spectrometry-based assays were used to measure %p-tau217 and amyloid beta (Aβ)42/40 ratio in blood samples from 583 individuals with suspected AD (53% positron emission tomography [PET] positive by Centiloid > 25). An algorithm (PrecivityAD2 test) was developed using these plasma biomarkers to identify brain amyloidosis by PET.

RESULTS

The area under the receiver operating characteristic curve (AUC-ROC) for %p-tau217 (0.94) was statistically significantly higher than that for p-tau217 concentration (0.91). The AUC-ROC for the PrecivityAD2 test output, the Amyloid Probability Score 2, was 0.94, yielding 88% agreement with amyloid PET. Diagnostic performance of the APS2 was similar by ethnicity, sex, age, and apoE4 status.

DISCUSSION: The PrecivityAD2 blood test showed strong clinical validity, with excellent agreement with brain amyloidosis by PET.

Для цитирования: Meyer Matthew R, Kirmess Kristopher M, Eastwood Stephanie, Wente-Roth Traci L, Irvin Faith, Holubasch Mary S, Venkatesh Venky, Fogelman Ilana, Monane Mark, Hanna Lucy, Rabinovici Gil D, Siegel Barry A, Whitmer Rachel A, Apgar Charles, Bateman Randall J, Holtzman David M, Irizarry Michael, Verbel David, Sachdev Pallavi, Ito Satoshi, Contois John, Yarasheski Kevin E, Braunstein Joel B, Verghese Philip B, West Tim. Clinical validation of the PrecivityAD2 blood test: A mass spectrometry-based test with algorithm combining %p-tau217 and Aβ42/40 ratio to identify presence of brain amyloid.. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2024. DOI: 10.1002/alz.13764.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.